Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study
- PMID: 28945293
- DOI: 10.1002/hed.24895
Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study
Abstract
Background: Some complications of radioiodine therapy have been reported, but the involvement of the eyes and adnexa is rarely discussed. The purpose of this study was to determine the correlation among ocular surface changes, xerostomia, and changes in the nasal mucosa associated with radioiodine therapy.
Methods: Patients subjected to radioiodine therapy (group 1) or not subjected (group 2) were prospectively evaluated by examinations of the ocular surface and tear film, saliva production, and nasal endoscopy. Ocular and nasal symptoms and xerostomia were evaluated using questionnaires.
Results: Evaluation of the ocular surface did not indicate significant differences between the groups. Nasal endoscopy revealed higher mucosal pallor in group 1 and worsening of the endoscopic appearance. Worsening of ocular symptoms and nasal symptoms, xerostomia, and a significant decrease in salivary production was also observed in group 1.
Conclusion: Subjective worsening of xerostomia, xerophthalmia, nasal symptoms, and changes in the nasal mucosa in group 1 was observed.
Keywords: diseases of the lacrimal system; drug-related side effects and adverse reactions; iodine radioisotopes; neoplasms of the thyroid gland/radiotherapy; radiation effects.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy.J Nucl Med. 2001 May;42(5):738-43. J Nucl Med. 2001. PMID: 11337569
-
Effects of Radioiodine Treatment on Salivary Gland Function in Patients with Differentiated Thyroid Carcinoma: A Prospective Study.J Nucl Med. 2016 Nov;57(11):1685-1691. doi: 10.2967/jnumed.115.169888. Epub 2016 Jun 23. J Nucl Med. 2016. PMID: 27339871 Clinical Trial.
-
Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.Strahlenther Onkol. 1999 Nov;175 Suppl 4:6-12. Strahlenther Onkol. 1999. PMID: 10584133 Clinical Trial.
-
Radioiodine therapy for papillary and follicular thyroid carcinoma.Eur J Nucl Med Mol Imaging. 2002 Aug;29 Suppl 2:S479-85. doi: 10.1007/s00259-002-0810-9. Epub 2002 May 9. Eur J Nucl Med Mol Imaging. 2002. PMID: 12192549 Review.
-
[Radioiodine in the treatment of generalized papillary and follicular thyroid carcinoma].Duodecim. 2014;130(6):573-9. Duodecim. 2014. PMID: 24724456 Review. Finnish.
Cited by
-
Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?Hormones (Athens). 2021 Dec;20(4):669-678. doi: 10.1007/s42000-021-00304-3. Epub 2021 Jun 18. Hormones (Athens). 2021. PMID: 34143403 Review.
-
Update on lacrimal apparatus dysfunction associated with differentiated thyroid cancer after I-131 therapy.Int Ophthalmol. 2024 Jun 23;44(1):257. doi: 10.1007/s10792-024-03192-9. Int Ophthalmol. 2024. PMID: 38909080 Review.
-
Patient‑reported outcome measures for assessing health‑related quality of life in patients with differentiated thyroid cancer: a systematic review.Int J Surg. 2025 Jan 1;111(1):1311-1329. doi: 10.1097/JS9.0000000000001974. Int J Surg. 2025. PMID: 39028114 Free PMC article.
-
[The lacrimal apparatus as an organ at risk during radionuclide therapy].Probl Endokrinol (Mosk). 2024 Feb 27;70(1):13-17. doi: 10.14341/probl13163. Probl Endokrinol (Mosk). 2024. PMID: 38433537 Free PMC article. Russian.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical